Comparison of two laboratory assays for the investigation of fibrin gel porosity [3]

Thrombosis and Haemostasis

Volumn 98, Issue 6, 2007, Pages 1386-1388

  Antovic, Aleksandra ^a   Jörneskog, Gun ^a   Wallen, N Håkan ^a  

^a DANDERYD HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; FIBRIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN;

ADULT; AGED; BLOOD ANALYSIS; BLOOD CLOTTING TIME; BLOOD SAMPLING; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DIABETIC HYPERTENSION; DIABETIC RETINOPATHY; DIET RESTRICTION; DISEASE DURATION; DRUG INTERMITTENT THERAPY; GEL; HUMAN; HUMAN TISSUE; INSULIN DEPENDENT DIABETES MELLITUS; INTERMETHOD COMPARISON; LABORATORY TEST; LETTER; POROSITY; PRIORITY JOURNAL; RANK SUM TEST; RELIABILITY; REPRODUCIBILITY; SENSITIVITY ANALYSIS; SPECTROPHOTOMETRY;

AGED; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 1; FIBRIN; GELS; HEMATOLOGIC TESTS; HUMANS; MIDDLE AGED; PERMEABILITY; POROSITY; REPRODUCIBILITY OF RESULTS;

EID: 36949018945     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH07-06-0390     Document Type: Letter

References (18)

1. Blombäck B, Carlsson K, Fatah K, et al. Fibrin in human plasma: gel architectures governed by rate and nature of fibrinogen activation. Thromb Res 1994; 75: 521-538.
2. Blombäck B, Carlsson K, Hessel B, et al. Native fibrin gel networks observed by 3D microscopy, permeation and turbidity. Biochim Biophys Acta 1989; 997: 96-110.
3. Fatah K, Hamsten A, Blombäck B, et al. Fibrin gel net work characteristics and coronary heart disease: relations to plasma fibrinogen concentration, acute phase protein, serum lipoproteins and coronary atherosclerosis. Thromb Haemost 1992; 68: 130-135.
4. Fatah K, Silveira A, Tornvall P, et al. Proneness to formation of tight and rigid fibrin gel structure in men with myocardial infarction at young age. Thromb Haemost 1996; 76: 535-540.
5. Jörneskog G, Egberg N, Fagrell B, et al. Altered properties of the fibrin gel structure in patients with IDDM. Diabetologia 1996; 39: 1519-1523.
6. Kalani M, Silveira A, Blomback M, et al. Beneficial effects of dalteparin on haemostatic function and local tissue oxygenation in patients with diabetes, severe vascular disease and foot ulcers. Thromb Res 2007; 120: 653-661.
7. Jörneskog G, Fatah K, Blombäck M. Fibrin gel structure in diabetic patients before and during treatment with acetylsalicylic acid-a pilot study. Fibrinolysis Proteol 1998; 12: 360-365.
8. Jörneskog G, Hansson LO, Wallen NH, et al. Increased plasma fibrin gel porosity in patients with Type I diabetes during continuous subcutaneous insulin infusion. J Thromb Haemost 2003; 1: 1195-1201.
9. He S, Cao H, Antovic A, et al. Modifications of flow measurement to assay fibrin gel permeability in association with thrombin generation potential and/or fibrinogen clotting property. Blood Coagul Fibrinolysis 2005; 16: 61-67.
10. Nair CH, Azhar A, Dhall DP. Studies on fibrin network structure in human plasma. Part One: Methods for clinical application. Thromb Res 1991; 64: 455-476.
11. Pieters M, Jerling JC, Weisel JW. Effect of freeze-drying, freezing and frozen storage of blood plasma on fibrin network characteristics. Thromb Res 2002; 107: 263-269.
12. Mills JD, Ariens RA, Mansfield MW et al. Altered fibrin clot structure in the healthy relatives of patients with premature coronary artery disease. Circulation 2002; 106: 1938-1942.
13. Sjoland JA. A new optimized method for the determination of fibrin clot permeability. Blood Coagul Fibrinolysis. 2005; 16: 579-583.
14. Carr ME, Shen LL, Hermans J. Mass-length ratio of fibrin fibers from gel permeation and light scattering. Biopolymers 1977; 16: 1-15.
15. Fatah K, Beving H, Albåge A, et al. Acetylsalicylic acid may protect the patient by increasing fibrin gel porosity. Is withdrawing of treatment harmful to the patient? Eur Heart J 1996; 17: 1362-1366.
16. Williams S, Fatah K, Hjemdahl P, et al. Better increase in fibrin gel porosity by low dose than intermediate dose acetylsalicylic acid. Eur Heart J 1998; 19: 1666-1672.
17. Antovic A, Perneby C, Jacobsson Ekman GJ, et al. Marked increase of fibrin gel permeability with very low dose ASA treatment. A new argument to use low dose ASA treatment in the prevention of atherotrombotic disease? Thromb Res 2005; 116: 509-517.
18. He S, Ekman GJ, Hedner U. The effect of platelets on fibrin gel structure formed in the presence of recombinant factor VIIa in hemophilia plasma and in plasma from a patient with Glanzmann thrombasthenia. J Thromb Haemost 2005; 3: 272-279.